目的回顾性分析晚期非小细胞肺癌患者凝血纤溶指标的异常,进一步探讨其与临床病理特征的相关性。方法对101例初治晚期非小细胞肺癌患者分别测定血浆凝血酶原时间(PT)、活化部分凝血酶原时间(APTT)、纤维蛋白原(FIB)、血浆D-二聚体(D-D)、纤维蛋白原降解产物(FDP)、凝血酶时间(TT)和血小板(PLT)。结果 101例患者中,PLT高于正常者有29例(28.7%),PT缩短者有29例(28.7%),APTT缩短者有9例(8.9%),FIB升高者有27例(26.7%),D-D升高者有19例(18.8%),FDP升高者有18例(17.8%),TT延长者有14例(13.9%)。结论肿瘤患者存在高凝状态,如何在临床中使用抗凝治疗,以及抗凝治疗能够改善患者的生存还需进一步的研究。 Objective To retrospectively analyze the abnormality of coagulation and fibrinolysis index in patients with advanced non-small cell lung cancer and to further explore its correlation with clinicopathological features. Methods Thirty patients with newly diagnosed advanced non-small cell lung cancer were enrolled in this study. Plasma prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), plasma D-dimer Fibrinogen Degradation Products (FDP), Thrombin Time (TT), and Platelets (PLT). Results Of the 101 patients, 29 (28.7%) had PLT higher than normal, 29 (28.7%) had PT shortened, 9 (8.9%) had shortened APTT, and 27 %). There were 19 cases (18.8%) with elevated DD, 18 cases (17.8%) with elevated FDP and 14 cases (13.9%) with TT prolongation. Conclusion There is a hypercoagulable state in patients with cancer, and how to use anticoagulant therapy in clinical practice and that anticoagulation therapy can improve patient survival need further study.